The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Growth factors for treating diabetic foot ulcers
Open accessAbstract
BACKGROUND: Foot ulcers are a major complication of diabetes mellitus, often leading to amputation. Growth factors derived from blood platelets, endothelium, or macrophages could potentially be an important treatment for these wounds but they may also confer risks. OBJECTIVES: To assess the benefits and harms of growth factors for foot ulcers in patients with type 1 or type 2 diabetes mellitus. SEARCH METHODS: In March 2015 we searched the Cochrane Wounds Group Specialised Register, The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), Ovid MEDLINE, Ovid MEDLINE (In-Process & Other Non-Indexed Citations, Ovid EMBASE and EBSCO CINAHL. There were no restrictions with respect to language, date of publication or study setting. SELECTION CRITERIA: Randomised clinical trials in any setting, recruiting people with type 1 or type 2 diabetes mellitus diagnosed with a foot ulcer. Trials were eligible for inclusion if they compared a growth factor plus standard care (e.g., antibiotic therapy, debridement, wound dressings) versus placebo or no growth factor plus standard care, or compared different growth factors against each other. We considered lower limb amputation (minimum of one toe), complete healing of the foot ulcer, and time to complete healing of the diabetic foot ulcer as the primary outcomes. DATA COLLECTION AND ANALYSIS: Independently, we selected randomised clinical trials, assessed risk of bias, and extracted data in duplicate. We estimated risk ratios (RR) for dichotomous outcomes. We measured statistical heterogeneity using the I(2) statistic. We subjected our analyses to both fixed-effect and random-effects model analyses. MAIN RESULTS: We identified 28 randomised clinical trials involving 2365 participants. The cause of foot ulcer (neurologic, vascular, or combined) was poorly defined in all trials. The trials were conducted in ten countries. The trials assessed 11 growth factors in 30 comparisons: platelet-derived wound healing formula, autologous growth factor, allogeneic platelet-derived growth factor, transforming growth factor β2, arginine-glycine-aspartic acid peptide matrix, recombinant human platelet-derived growth factor (becaplermin), recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human vascular endothelial growth factor, recombinant human lactoferrin, and recombinant human acidic fibroblast growth factor. Topical intervention was the most frequent route of administration. All the trials were underpowered and had a high risk of bias. Pharmaceutical industry sponsored 50% of the trials.Any growth factor compared with placebo or no growth factor increased the number of participants with complete wound healing (345/657 (52.51%) versus 167/482 (34.64%); RR 1.51, 95% CI 1.31 to 1.73; I(2) = 51%, 12 trials; low quality evidence). The result is mainly based on platelet-derived wound healing formula (36/56 (64.28%) versus 7/27 (25.92%); RR 2.45, 95% 1.27 to 4.74; I(2) = 0%, two trials), and recombinant human platelet-derived growth factor (becaplermin) (205/428 (47.89%) versus 109/335 (32.53%); RR 1.47, 95% CI 1.23 to 1.76, I(2)= 74%, five trials).In terms of lower limb amputation (minimum of one toe), there was no clear evidence of a difference between any growth factor and placebo or no growth factor (19/150 (12.66%) versus 12/69 (17.39%); RR 0.74, 95% CI 0.39 to 1.39; I(2) = 0%, two trials; very low quality evidence). One trial involving 55 participants showed no clear evidence of a difference between recombinant human vascular endothelial growth factor and placebo in terms of ulcer-free days following treatment for diabetic foot ulcers (RR 0.64, 95% CI 0.14 to 2.94; P value 0.56, low quality of evidence)Although 11 trials reported time to complete healing of the foot ulcers in people with diabetes , meta-analysis was not possible for this outcome due to the unique comparisons within each trial, failure to report data, and high number of withdrawals. Data on quality of life were not reported. Growth factors showed an increasing risk of overall adverse event rate compared with compared with placebo or no growth factor (255/498 (51.20%) versus 169/332 (50.90%); RR 0.83; 95% CI 0.72 to 0.96; I(2) = 48%; eight trials; low quality evidence). Overall, safety data were poorly reported and adverse events may have been underestimated. AUTHORS' CONCLUSIONS: This Cochrane systematic review analysed a heterogeneous group of trials that assessed 11 different growth factors for diabetic foot ulcers. We found evidence suggesting that growth factors may increase the likelihood that people will have complete healing of foot ulcers in people with diabetes. However, this conclusion is based on randomised clinical trials with high risk of systematic errors (bias). Assessment of the quality of the available evidence (GRADE) showed that further trials investigating the effect of growth factors are needed before firm conclusions c
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
GRADE guidelines 6. Rating the quality of evidence—imprecision
Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., Devereaux, P. J., Montori, V. M., Freyschuss, B., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.012 · Cited by 2,693
What is meant by intention to treat analysis? Survey of published randomised controlled trials
Hollis, S., & Campbell, F. (1999) · BMJ · doi:10.1136/bmj.319.7211.670 · Cited by 2,160
GRADE guidelines: 2. Framing the question and deciding on important outcomes
Guyatt, G. H., Oxman, A. D., Kunz, R., Atkins, D., Brozek, J., Vist, G., Alderson, P., Glasziou, P., Falck-Ytter, Y., & Schünemann, H. J. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.012 · Cited by 1,911
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · Trials · doi:10.1186/1745-6215-11-32 · Cited by 1,871
GRADE guidelines: 5. Rating the quality of evidence—publication bias
Guyatt, G. H., Oxman, A. D., Montori, V., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Djulbegovic, B., Atkins, D., Falck-Ytter, Y., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.011 · Cited by 1,819
Research works printed but not linked: 151
- Afshari, 2005, Efficacy of topical epidermal growth factor in healing diabetic foot ulcers, Therapy, 2, 759, 10.2217/14750708.2.5.759 · doi:10.2217/14750708.2.5.759
- Agrawal, 2009, Use of a platelet-derived growth factor gel in chronic diabetic foot ulcers, Diabetic Foot Journal, 12, 80
- Bhansali, 2009, Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?, Diabetes Research and Clinical Practice, 83, e13, 10.1016/j.diabres.2008.10.005 · DOI
- Chen, 2004, Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot, Modern Nursing, 10, 274
- d'Hemecourt, 1998, Sodium carboxymethyl cellulose aqueous-based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers, Wounds, 10, 69
- Driver, 2006, A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non-healing diabetic foot ulcers, Diabetes, 55, A25
- Driver, 2006, A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers, Ostomy/Wound Management, 52, 68
- Fernández-Montequin, 2007, Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation, International Wound Journal, 4, 333, 10.1111/j.1742-481X.2007.00344.x · DOI
- Fernández-Montequín, 2009, Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure, International Wound Journal, 6, 67, 10.1111/j.1742-481X.2008.00561.x · DOI
- Fernández-Montequín, 2009, Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study, International Wound Journal, 6, 432, 10.1111/j.1742-481X.2009.00641.x · DOI
- Hanft, 2008, Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers, Journal of Wound Care, 17, 30-2, 34-7, 10.12968/jowc.2008.17.1.27917 · DOI · Paper page
- Kwon, 2006, Results of a phase I, randomized, double-blind, placebo-controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers, Wound Management, 54, 102
- Hardikar, 2005, Efficacy of recombinant human platelet-derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double-blind, placebo-controlled study in India, Wounds, 17, 141
- Holloway, 1993, A randomised controlled dose response trial of activated platelet supernatant, topical CT-102 in chronic, non healing diabetic wounds, Wounds, 5, 198–206
- Jaiswal, 2010, Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers, Indian Journal of Surgery, 72, 31, 10.1007/s12262-010-0005-8 · DOI
- Kakagia, 2007, Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial, Journal of Diabetes and its Complications, 21, 387, 10.1016/j.jdiacomp.2007.03.006 · DOI
- Landsman, 2010, Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis, Journal of the American Podiatric Medical Association, 100, 155, 10.7547/1000155 · DOI
- Parish, 2009, Diabetic foot ulcers: a randomized multicenter study comparing a moisture-controlling dressing with a topical growth factor, Journal of the American Academy of Dermatology, 60, AB202
- Lyons, 2007, Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study, American Journal of Surgery, 193, 49, 10.1016/j.amjsurg.2006.07.010 · DOI
- Niezgoda, 2005, Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers, Advances in Skin and Wound Care, 18, 258, 10.1097/00129334-200506000-00012 · DOI · Paper page
- Richard, 1995, Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double-blind, placebo-controlled study, Diabetes Care, 18, 64, 10.2337/diacare.18.1.64 · DOI · Paper page
- Robson, 2002, Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose-ranging trial, Journal of Applied Research, 2, 133
- Saldalamacchia, 2004, A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers, Nutrition Metabolism and Cardiovascular Diseases, 14, 395, 10.1016/S0939-4753(04)80029-2 · doi:10.1016/s0939-4753(04)80029-2
- Saldalamacchia, 2004, Use of autologous platelet gel for the treatment of diabetic foot ulcers, Giornale Italiano di Diabetologia e Metabolismo, 24, 103
- Steed, 1992, Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT-102 activated platelet supernatant, topical versus placebo, Diabetes Care, 15, 1598–604, 10.2337/diacare.15.11.1598 · DOI · Paper page
- Steed, 2006, Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers, Plastic and Reconstructive Surgery, 117 (Suppl7), 143, 10.1097/01.prs.0000222526.21512.4c · DOI · Paper page
- Steed, 1995, Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers, Journal of Vascular Surgery, 21, 71, 10.1016/S0741-5214(95)70245-8 · DOI · Paper page
- Steed, 1995, Promotion and acceleration of diabetic ulcer healing by arginine glycine-aspartic acid (RGD) peptide matrix, Diabetes Care, 18, 39–46, 10.2337/diacare.18.1.39 · DOI
- Steed, 1996, Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets, Wound Repair and Regeneration, 4, 230, 10.1046/j.1524-475X.1996.40210.x · doi:10.1046/j.1524-475x.1996.40210.x
- Tan, 2008, Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients, Journal of Health Science, 54, 432, 10.1248/jhs.54.432 · DOI
- Tsang, 2003, Human epidermal growth factor enhances healing of diabetic foot ulcers, Diabetes Care, 26, 1856, 10.2337/diacare.26.6.1856 · DOI · Paper page
- Uchi, 2009, Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer, European Journal of Dermatology, 19, 461, 10.1684/ejd.2009.0750 · DOI · Paper page
- Viswanathan, 2006, A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D 150) in healing diabetic foot ulcers, Wounds, 18, 186
- Wieman, 1998, Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study, Diabetes Care, 21, 822, 10.2337/diacare.21.5.822 · DOI · Paper page
- Acosta, 2006, Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds, International Wound Journal, 3, 232, 10.1111/j.1742-481X.2006.00237.x · DOI
- Embil, 2000, Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy, Wound Repair and Regeneration, 8, 162, 10.1046/j.1524-475x.2000.00162.x · DOI · Paper page
- Hong, 2006, Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers, Annals of Plastic Surgery, 56, 394, 10.1097/01.sap.0000198731.12407.0c · DOI · Paper page
- Miller, 1999, Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers, The Journal of Foot and Ankle Surgery, 38, 227, 10.1016/S1067-2516(99)80058-1 · DOI
- Mohan, 2007, Recombinant human epidermal growth factor (REGEN-D 150): effect on healing of diabetic foot ulcers, Diabetes Research and Clinical Practice, 78, 405, 10.1016/j.diabres.2007.06.004 · DOI
- Saad Setta, 2011, Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: a comparative study, International Wound Journal, 8, 307, 10.1111/j.1742-481X.2011.00797.x · DOI · Paper page
- Tuyet, 2009, The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results, International Wound Journal, 6, 159, 10.1111/j.1742-481X.2009.00594.x · doi:10.1111/j.1742-481x.2009.00594.x
- Yera-Alos, 2013, Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers, BMC Pharmacology and Toxicology, 14, 44, 10.1186/2050-6511-14-44 · DOI
- Gomez-Villa, 2014, Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double-blinded controlled trial, Wound Repair and Regeneration, 22, 497, 10.1111/wrr.12187 · DOI
- Morimoto, 2013 Part A, Novel collagen/gelatin scaffold with sustained release of basic fibroblast growth factor: clinical trial for chronic skin ulcers, Tissue engineering, 19, 1931, 10.1089/ten.tea.2012.0634 · DOI
- Singla, 2014, Efficacy of topical application of beta urogastrone (recombinant human epidermal growth factor) in Wagner's Grade 1 and 2 diabetic foot ulcers: Comparative analysis of 50 patients, Journal of Natural Science, Biology and Medicine, 5, 273, 10.4103/0976-9668.136160 · doi:10.4103/0976-9668.136160
- Young, 1992, The treatment of diabetic neuropathic foot ulcers with biosynthetic platelet derived growth factor, Diabetic Medicine, S42
- Abbott, 2002, The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort, Diabetes Medicine, 19, 377, 10.1046/j.1464-5491.2002.00698.x · DOI · Paper page
- Albert, 2002, Cost-effective management of recalcitrant diabetic foot ulcers, Clinics in Podiatric Medicine and Surgery, 19, 483, 10.1016/S0891-8422(02)00018-6 · doi:10.1016/s0891-8422(02)00018-6
- Ali S Fareed A Humail S Basit A Ahmedani M Fawwad A The personal cost of diabetic foot disease in the developing world - a study from Pakistan Diabetic Medicine 2008 1231 3 · DOI
- Amery, 2005, Growth factors and the management of the diabetic foot, Diabetic Medicine, 22 Suppl 1, 12, 10.1111/j.1464-5491.2005.1531f.x · DOI
- Andersen, 2004, Technology evaluation: rh lactoferrin, Agennix, Current Opinion in Molecular Therapeutics, 6, 344
- Armstrong, 2008, Quality of life in healing diabetic wounds: does the end justify the means?, Journal of Foot and Ankle Surgery, 47, 278, 10.1053/j.jfas.2008.02.015 · DOI
- Ashry, 1998, Cost of diabetes-related amputations in minorities, The Journal of Foot and Ankle Surgery, 37, 186, 10.1016/S1067-2516(98)80108-7 · DOI
- Bakker, 2012, The development of global consensus guidelines on the management and prevention of the diabetic foot 2011, Diabetes/Metabolism Research and Reviews, 28, 116, 10.1002/dmrr.2254 · DOI
- Bakker, 2012, Practical guidelines on the management and prevention of the diabetic foot 2011, Diabetes/Metabolism Research and Reviews, 28, 225, 10.1002/dmrr.2253 · DOI · Paper page
- Barrientos, 2008, Growth factors and cytokines in wound healing, Wound Repair and Regeneration, 16, 585, 10.1111/j.1524-475X.2008.00410.x · DOI · Paper page
- Bartus, 2004, Reducing the incidence of foot ulceration and amputation in diabetes, Current Diabetes Reports, 4, 413, 10.1007/s11892-004-0049-x · DOI
- Basch, 2012, Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective, JAMA, 307, 1636, 10.1001/jama.2012.466 · DOI · Paper page
- Beckert, 2006, A new wound-based severity score for diabetic foot ulcers: a prospective analysis of 1,000 patients, Diabetes Care, 29, 988, 10.2337/dc05-2431 · doi:10.2337/dc05-2431
- Bennett, 2003, Growth factors in the treatment of diabetic foot ulcers, The British Journal of Surgery, 90, 133, 10.1002/bjs.4019 · DOI · Paper page
- Boulton, 2005, The global burden of diabetic foot disease, Lancet, 366, 1719, 10.1016/S0140-6736(05)67698-2 · DOI · Paper page
- Boulton, 2008, The diabetic foot: grand overview, epidemiology and pathogenesis, Diabetes/Metabolism Research and Reviews, 24 (Suppl 1), 3, 10.1002/dmrr.833 · DOI · Paper page
- Boutoille, 2008, Quality of life with diabetes-associated foot complications: comparison between lower-limb amputation and chronic foot ulceration, Foot and Ankle International, 29, 1074, 10.3113/FAI.2008.1074 · DOI
- Buchberger, 2010, The importance of growth factors for the treatment of chronic wounds in the case of diabetic foot ulcers, GMS Health Technology Assessment, 6, Doc12
- Buchmayer, 2011, Actovegin(R): a biological drug for more than 5 decades, Wiener Medizinische Wochenschrift, 161, 80, 10.1007/s10354-011-0865-y · doi:10.1007/s10354-011-0865-y
- Chao, 2009, Microvascular dysfunction in diabetic foot disease and ulceration, Diabetes/Metabolism Research and Reviews, 25, 604, 10.1002/dmrr.1004 · DOI · Paper page
- Clarke, 2007, Standardising outcomes for clinical trials and systematic reviews, Trials, 8, 39, 10.1186/1745-6215-8-39 · DOI · Paper page
- Cruciani, 2009, Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006810 · doi:10.1002/14651858.cd006810
- Enoch, 2008, Basic science of wound healing, Surgery, 26, 31
- Figueroa-Romero, 2008, Mechanisms of disease: the oxidative stress theory of diabetic neuropathy, Reviews in Endocrine & Metabolic Disorders, 9, 301, 10.1007/s11154-008-9104-2 · DOI · Paper page
- Foster, 2009, Platelet-rich plasma: from basic science to clinical applications, The American Journal of Sports Medicine, 37, 2259, 10.1177/0363546509349921 · DOI · Paper page
- Girod, 2003, An economic evaluation of the cost of diabetic foot ulcers: results of a retrospective study on 239 patients, Diabetes and Metabolism, 29, 269, 10.1016/S1262-3636(07)70036-8 · DOI
- Goodridge, 2006, Quality of life of adults with unhealed and healed diabetic foot ulcers, Foot and Ankle International, 27, 274, 10.1177/107110070602700408 · DOI
- Grazul-Bilska, 2003, Wound healing: the role of growth factors, Drugs of Today, 39, 787, 10.1358/dot.2003.39.10.799472 · DOI · Paper page
- Guyatt, 2011, GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology, Journal of Clinical Epidemiology, 64, 380, 10.1016/j.jclinepi.2010.09.011 · DOI · Paper page
- Guyatt, 2011, GRADE guidelines: 7. Rating the quality of evidence - inconsistency, Journal of Clinical Epidemiology, 64, 1294, 10.1016/j.jclinepi.2011.03.017 · DOI · Paper page
- Guyatt, 2011, GRADE guidelines: 8. Rating the quality of evidence - indirectness, Journal of Clinical Epidemiology, 64, 1303, 10.1016/j.jclinepi.2011.04.014 · DOI · Paper page
- Guyatt, 2013, GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes, Journal of Clinical Epidemiology, 66, 151, 10.1016/j.jclinepi.2012.01.006 · DOI · Paper page
- Habib, 2010, Cost-effectiveness analysis of medical intervention in patients with early detection of diabetic foot in a tertiary care hospital in Bangladesh, Journal of Diabetes and its Complications, 24, 259, 10.1016/j.jdiacomp.2008.12.005 · DOI
- Herber, 2007, A systematic review on the impact of leg ulceration on patients' quality of life, Health and Quality of Life Outcomes, 25, 44, 10.1186/1477-7525-5-44 · DOI · Paper page
- Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
- Hinchliffe, 2008, A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes, Diabetes/Metabolism Research and Reviews, 24, 119–44
- Humphrey, 1996, Diabetes and nontraumatic lower extremity amputations. Incidence, risk factors, and prevention - a 12-year follow-up study in Nauru, Diabetes Care, 19, 710, 10.2337/diacare.19.7.710 · doi:10.2337/diacare.19.7.710
- International Conference on Harmonisation Expert Working Group, 1997, International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR & ICH Guidelines, 1
- Ince, 2007, The association between baseline characteristics and the outcome of foot lesions in a UK population with diabetes, Diabetic Medicine, 24, 977, 10.1111/j.1464-5491.2007.02189.x · DOI
- Ince, 2008, Use of the SINBAD classification system and score in comparing outcome of foot ulcer management on three continents, Diabetes Care, 31, 964, 10.2337/dc07-2367 · DOI · Paper page
- Ioannidis, 2004, Better reporting of harms in randomized trials: an extension of the CONSORT statement, Annals of Internal Medicine, 141, 781, 10.7326/0003-4819-141-10-200411160-00009 · DOI · Paper page
- Ioannidis, 2010, Meta-research: the art of getting it wrong, Research Synthesis Methods, 1, 169, 10.1002/jrsm.19 · DOI · Paper page
- Iversen, 2008, History of and factors associated with diabetic foot ulcers in Norway: the Nord-Trøndelag Health Study, Scandinavian Journal of Public Health, 36, 62, 10.1177/1403494807085314 · DOI
- Izumi, 2009, Mortality of first-time amputees in diabetics: a 10-year observation, Diabetes Research and Clinical Practice, 83, 126, 10.1016/j.diabres.2008.09.005 · DOI
- Jeffcoate, 2003, Diabetic Foot Ulcers, Lancet, 361, 1545, 10.1016/S0140-6736(03)13169-8 · DOI · Paper page
- Jeffcoate, 2004, Amputation as a marker of the quality of foot care in diabetes, Diabetologia, 47, 2051, 10.1007/s00125-004-1584-3 · DOI · Paper page
- Jeffcoate, 2005, The incidence of amputation in diabetes, Acta Chirurgica Belgica, 105, 140, 10.1080/00015458.2005.11679687 · doi:10.1080/00015458.2005.11679687
- Kanade, 2007, Re-amputation occurrence in the diabetic population in South Wales, UK, International Wound Journal, 4, 344, 10.1111/j.1742-481X.2007.00313.x · doi:10.1111/j.1742-481x.2007.00313.x
- Kinmond, 2003, 'Loss of self': a psychosocial study of the quality of life of adults with diabetic foot ulceration, Journal of Tisssue Viability, 13, 6-8, 10, 12, 10.1016/S0965-206X(03)80025-6 · DOI
- Köveker, 2000, Growth factors in clinical practice, International Journal of Clinical Practice, 54, 590, 10.1111/j.1742-1241.2000.tb10933.x · DOI
- Lacci, 2010, Platelet-rich plasma: support for its use in wound healing, The Yale Journal of Biology and Medicine, 83, 1
- Lantis, 2009, Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer, Advances in Skin and Wound Care, 22, 167, 10.1097/01.ASW.0000305466.25177.a8 · DOI
- Lavery, 1996, Classification of diabetic foot wounds, The Journal of Foot and Ankle Surgery, 35, 528, 10.1016/S1067-2516(96)80125-6 · DOI · Paper page
- Lavery, 2008, Reevaluating the way we classify the diabetic foot: restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot, Diabetes Care, 31, 154, 10.2337/dc07-1302 · DOI · Paper page
- Lavery, 2009, Risk factors for developing osteomyelitis in patients with diabetic foot wounds, Diabetes Research and Clinical Practice, 83, 347, 10.1016/j.diabres.2008.11.030 · DOI · Paper page
- Lee, 1993, Lower-extremity amputation. Incidence, risk factors, and mortality in the Oklahoma Indian Diabetes Study, Diabetes, 42, 876, 10.2337/diab.42.6.876 · doi:10.2337/diab.42.6.876
- Lefebvre C Manheimer E Glanville J on behalf of the Cochrane Information Retrieval Methods Group Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
- Lehto, 1996, Risk factors predicting lower extremity amputations in patients with NIDDM, Diabetes Care, 19, 607, 10.2337/diacare.19.6.607 · DOI · Paper page
- Leymarie, 2005, Factors associated with diabetic patients at high risk for foot ulceration, Diabetes and Metabolism, 31, 603, 10.1016/S1262-3636(07)70238-0 · DOI
- Lipsky, 2004, Diagnosis and treatment of diabetic foot infections, Clinical Infectious Disease, 39, 885, 10.1086/424846 · DOI · Paper page
- Meatherall, 2005, Disability and quality of life in Canadian aboriginal and non-aboriginal diabetic lower-extremity amputees, Archives of Physical Medicine and Rehabilitation, 86, 1594, 10.1016/j.apmr.2004.11.026 · DOI
- Milman, 2001, Diabetic foot: evaluation of evolution and hospital cost of hospitalized patients in Conjunto Hospitalar de Sorocaba, Arquivos Brasileiros de Endocrinologia e Metabologia, 45, 447, 10.1590/S0004-27302001000500007 · doi:10.1590/s0004-27302001000500007
- Moss, 1996, Long-term incidence of lower-extremity amputations in a diabetic population, Archives of Family Medicine, 5, 391, 10.1001/archfami.5.7.391 · DOI
- Nabuurs-Franssen, 2005, Health-related quality of life of diabetic foot ulcer patients and their caregivers, Diabetologia, 48, 1906, 10.1007/s00125-005-1856-6 · DOI · Paper page
- Nelson, 1988, Lower-extremity amputations in NIDDM. 12-year follow-up study in Pima Indians, Diabetes Care, 11, 8, 10.2337/diacare.11.1.8 · DOI · Paper page
- O'Meara, 2000, Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration, Health Technology Assessment, 4, 1
- Oyibo, 2001, The effects of ulcer size and site, patient’s age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers, Diabetic Medicine, 18, 133, 10.1046/j.1464-5491.2001.00422.x · DOI · Paper page
- Papanas, 2007, Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?, The International Journal of Lower Extremity Wounds, 6, 37, 10.1177/1534734606298416 · DOI
- Papanas, 2008, Becaplermin gel in the treatment of diabetic neuropathic foot ulcers, Clinical Interventions in Aging, 3, 233, 10.2147/CIA.S1106 · DOI
- Papanas, 2010, Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers, Drug Safety, 33, 455, 10.2165/11534570-000000000-00000 · DOI
- Porta, 2008, A Dictionary of Epidemiology
- Pradhan, 2009, Inflammation and neuropeptides: the connection in diabetic wound healing, Expert Reviews in Molecular Medicine, 11, e2, 10.1017/S1462399409000945 · DOI · Paper page
- Price, 2004, The diabetic foot: quality of life, Clinical Infectious Diseases, 39, 129, 10.1086/383274 · DOI
- Quattrini, 2008, Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy, Diabetes Care, 31, 140, 10.2337/dc07-1556 · DOI
- Ramsey, 1999, Incidence, outcomes, and cost of foot ulcers in patients with diabetes, Diabetes Care, 22, 382, 10.2337/diacare.22.3.382 · DOI · Paper page
- Rathur, 2007, The diabetic foot, Clinics in Dermatology, 25, 109, 10.1016/j.clindermatol.2006.09.015 · DOI
- Redekop, 2004, Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments, Diabetes and Metabolism, 30, 549, 10.1016/S1262-3636(07)70154-4 · DOI
- Ribu, 2008, A longitudinal study of patients with diabetes and foot ulcers and their health-related quality of life: wound healing and quality-of-life changes, Journal of Diabetes Complications, 22, 400, 10.1016/j.jdiacomp.2007.06.006 · DOI
- Richard, 2008, Epidemiology of diabetic foot problems, La Revue Médicine Interne, 29, 222, 10.1016/S0248-8663(08)73949-3 · DOI
- Rith-Najarian, 1992, Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteria, Diabetes Care, 15, 1386, 10.2337/diacare.15.10.1386 · DOI · Paper page
- Rozman, 2007, Use of platelet growth factors in treating wounds and soft-tissue injuries, Acta Dermatovenerologica Alpina, Panonica, et Adriatica, 16, 156
- Schaper, 2004, Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies, Diabetes/Metabolism Research and Reviews, 20, 90, 10.1002/dmrr.464 · DOI · Paper page
- Schaper, 2012, Reducing lower leg amputations in diabetes: a challenge for patients, healthcare providers and the healthcare system, Diabetologia, 55, 1869, 10.1007/s00125-012-2588-z · DOI
- Schaper, 2012, Diagnosis and treatment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress report of the International Working Group on the Diabetic Foot, Diabetes/Metabolism Research and Reviews, 28, 218, 10.1002/dmrr.2255 · DOI · Paper page
- Selby, 2012, The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda, JAMA, 307, 1583, 10.1001/jama.2012.500 · DOI · Paper page
- Sheehan, 2006, Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial, Plastic and Reconstructive Surgery, 117(7 Suppl), 239, 10.1097/01.prs.0000222891.74489.33 · DOI · Paper page
- Sibbald, 2008, The biology of chronic foot ulcers in persons with diabetes, Diabetes/Metabolism Research and Reviews, 24, 25, 10.1002/dmrr.847 · DOI · Paper page
- Siriwardana, 2007, The cost of diabetic foot conditions, The Ceylon Medical Journal, 52, 89, 10.4038/cmj.v52i3.966 · doi:10.4038/cmj.v52i3.966
- Skoutas, 2009, Risk factors for ipsilateral reamputation in patients with diabetic foot lesions, The International Journal of Lower Extremity Wounds, 8, 69, 10.1177/1534734609334808 · DOI
- Smith, 2004, The cost of managing diabetic foot ulceration in an Irish hospital, Irish Journal of Medical Science, 173, 89, 10.1007/BF02914564 · DOI
- Smyth, 2009, Platelet functions beyond hemostasis, Journal of Thrombosis and Haemotasis, 7, 1759, 10.1111/j.1538-7836.2009.03586.x · DOI · Paper page
- Valensi, 2005, Quality of life and clinical correlates in patients with diabetic foot ulcers, Diabetes and Metabolism, 31, 263, 10.1016/S1262-3636(07)70193-3 · DOI
- Acker, 2000, Cost and resource utilization for prevention and treatment of foot lesions in a diabetic foot clinic in Belgium, Diabetes Research and Clinical Practice, 50, 87, 10.1016/S0168-8227(00)00157-1 · DOI
- Houtum, 2008, Amputations and ulceration; pitfalls in assessing incidence, Diabetes/Metabolism Research and Reviews, 24, 14, 10.1002/dmrr.826 · doi:10.1002/dmrr.826
- Veves, 1992, The risk of foot ulceration in diabetic patients with high foot pressure: a prospective study, Diabetologia, 35, 660, 10.1007/BF00400259 · DOI · Paper page
- Viswanathan, 2005, Profile of diabetic foot complications and its associated complications - a multicentric study from India, The Journal of Association Physicians of India, 53, 933
- Viswanathan, 2006, A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-DTM 150) in healing diabetic foot ulcers, Wounds, 18, 186
- Wagner, 1981, The dysvascular foot: a system of diagnosis and treatment, Foot and Ankle International, 2, 64, 10.1177/107110078100200202 · DOI · Paper page
- Weinberg, 2003, The therapeutic potential of lactoferrin, Expert Opinion on Investigational Drugs, 12, 841, 10.1517/13543784.12.5.841 · DOI
- Wieman, 1998, Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group, American Journal of Surgery, 176, 74S, 10.1016/S0002-9610(98)00185-8 · DOI · Paper page
- Willrich, 2005, Health related quality of life, cognitive function, and depression in diabetic patients with foot ulcer or amputation. A preliminary study, Foot and Ankle International, 26, 128, 10.1177/107110070502600203 · DOI
- Winkley, 2007, Risk factors associated with adverse outcomes in a population-based prospective cohort study of people with their first diabetic foot ulcer, Journal of Diabetes and its Complications, 21, 341, 10.1016/j.jdiacomp.2007.09.004 · DOI
- Younes, 2004, Diabetic heel ulcers: a major risk factor for lower extremity amputation, Ostomy/Wound Management, 50, 50
- Young, 1994, The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study, Diabetes Care, 17, 557, 10.2337/diacare.17.6.557 · DOI · Paper page
- Ziyadeh, 2011, A matched cohort study of the risk of cancer in users of becaplermin, Advances in Skin and Wound Care, 24, 31, 10.1097/01.ASW.0000392922.30229.b3 · DOI
Cited by
Update on management of diabetic foot ulcers
Everett, E., & Mathioudakis, N. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13569 · Cited by 913
Wang, C., Wang, M., Xu, T., Zhang, X., Lin, C., Gao, W., Xu, H., Lei, B., & Mao, C. (2019) · Theranostics · doi:10.7150/thno.29766 · Cited by 908
Advanced drug delivery systems and artificial skin grafts for skin wound healing
Kim, H. S., Sun, X., Lee, J.-H., Kim, H.-W., Fu, X., & Leong, K. W. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.014 · Cited by 625
The Treatment of Impaired Wound Healing in Diabetes: Looking among Old Drugs
Spampinato, S. F., Caruso, G. I., De Pasquale, R., Sortino, M. A., & Merlo, S. (2020) · Pharmaceuticals · doi:10.3390/ph13040060 · Cited by 468
Advances in surgical applications of growth factors for wound healing
Yamakawa, S., & Hayashida, K. (2019) · Burns & Trauma · doi:10.1186/s41038-019-0148-1 · Cited by 347
Metadata
- Authors
- Martí-Carvajal, A. J., Gluud, C., Nicola, S., Simancas-Racines, D., Reveiz, L., Oliva, P., & Cedeño-Taborda, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2015-10-28
- Volume
- 2015
- Issue
- 10
- Pages
- CD008548-CD008548
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2117595314
- Cited by
- 192
- References
- 19
- FWCI
- 11.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Growth factors for treating diabetic foot ulcers. https://app.cochat.ai/papers/10.1002/14651858.cd008548.pub2
- The paper
- Martí-Carvajal, A. J., Gluud, C., Nicola, S., Simancas-Racines, D., Reveiz, L., Oliva, P., & Cedeño-Taborda, J. (2015). Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd008548.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.